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Abstract 
 
Postoperative infection following invasive surgical procedures is a significant cause 
for concern, particularly in spinal reconstructive surgery. The objective of the study was to 
compare the antibacterial efficacy of a novel zinc based glass polyalkenoate cement (Zn-
GPC) based on 0.04SrO-0.12CaO-0.36ZnO-0.48SiO2 glass, to a number of commercially 
available bone cements and fillers including Simplex P + Tobramycin (STob), Spineplex 
(Spine) and Novabone Putty (NPut). The agar diffusion test was performed on each material 
against E. coli, S. epidermidis, P. aeruginosa and S. Aureus. STob was found to produce large 
inhibition zones in each of the bacteria tested and was statistically significantly higher than 
any other material. The experimental Zn-GPC (BTSC) was found to exhibit antibacterial 
properties in both E. coli and S. epidermidis. Neither Spine nor NPut showed any inhibitory 
effect in any of the bacteria tested. A study was also performed to determine the effect of 
antibiotic release from STob and the Zn-GPC (BTob) containing the antibiotic tobramycin 
(Tob). Antibacterial efficacy was found to increase with respect to maturation with BTob, 
whereas STob was found to decrease significantly over the time period 0 – 14 days. The final 
objective was to investigate any change in agar composition during the agar-diffusion test. 
Little change was observed for STob as antibiotic release cannot be determined using EDX. 
There was however an increase in Zn levels when analysing BTSC which suggests that Zn is 
playing a role in the antimicrobial nature of the Zn-GPC. No significant changes were 
observed for Spine or NPut.  
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 
 
Biomaterial associated infections are of major concern in surgery. Microorganisms are 
frequently introduced onto implant surfaces and subsequently into the body [1]. It has been 
reported that infection rates range from 0.8-1.2% in orthopaedic surgery (total hip arthroplasty) 
and 3.6-8.1% (closed fracture) to 17.5%-21.2% (open fractures) in trauma surgery[2]. Sepsis can 
ultimately lead to failure of the arthroplasty, causing the need for revision surgery, prolonged 
hospitalization and even death[3]. The field of biomedical engineering relies heavily on the 
interaction between the biomaterials and the surrounding physiological environment[4] and 
recently additives have been included in biomaterial design to increase antibacterial properties in 
an effort to extend the longevity of the implant. Some examples include antibiotic coatings, 
antibiotic-loaded collagen sheets and cement spacers[5] and antibiotic-loaded bone cements 
(ALBC). Commercially, ALBCs consist of a PMMA based cement with additions of antibiotics 
such as tobramycin, gentamicin[6, 7], vancomycin and erythromycin[7]. However concerns 
related to the use of ALBCs include the long term effectiveness of the released drug [6, 7] and 
promotion of bacterial resistance which is likely due to the long-term sub-therapeutic levels of 
antibiotic eluted from the cement[6]. Other additives such as chitosan and collagen have been 
added to materials in order to promote cell growth[7].  Chlorhexidine (CHX) has also been added 
to dental glass polyalkenoate cements (GPCs) to further improve antibacterial properties[8]. 
However CHX was found to interfere in the setting reaction of commercially tested GPCs 
resulting in reduced mechanical properties[8]. 
 GPCs, traditionally used in dental applications, generally contain ions that impart an 
antibacterial nature when used in an oral aqueous environment. The antimicrobial nature of these 
cements is predominantly due to the release of the fluoride ion (F
-
)[9-11] and also related to 
setting occuring at a low pH[12].  GPCs have the additional ability to uptake and re-release F
-
 
ions in a F
-
 rich aqueous environment, which can impart a prolonged antibacterial response[10]. 
However, translating GPCs from dental to orthopaedic applications highlights concerns relating 
to the composition of the material, in particular the presence of aluminium (Al) in the glass phase 
which can cause neurological[13, 14] and bone metabolic defects[15]. The GPCs produced in 
this work have zinc ions (Zn
2+
) substituting for Al ions (Al
3+
) as numerous studies report on the 
antibacterial efficiency[12, 16-18] and positive bone metabolic effects of Zn[19, 20].  
 For this study a range of commercially available materials were selected for testing. 
Simplex + Tobramycin (Stryker Howmedica, Limerick, Ireland) and Spineplex, (Stryker 
Howmedica, Limerick, Ireland) both of which are PMMA based materials used in load bearing 
applications in the skeleton. Novabone putty (Gian Medical, Birmingham, UK), a bioglass based 
bone filler was also included alongside an experimental Zn-GPC formulation. Each material was 
tested against a number of known bacteria that cause infection in surgical procedures; 
Escherichia coli, Staphlococcus epidermidis, Pseudomonas aeruginosa and Staphlococcus 
aureus. Of these, S. epidermidis and S. aureus are responsible, in most instances, for biomaterial 
related infections[21], due to the presence of adherent, multilayered biofilms on the surfaces of 
implanted biomedical devices which are less susceptible to antibiotics compared to their 
planktonic counterparts[22]. P. aeruginosa has been found to infect surgical procedures such as 
Total Knee Arthroplasty (TKA) [23], and is reported to be the cause of osteomyelitis in pelvic 
bones[24]. It has also, along with E. coli, been found to constitute 42% of polymicrobial 
infections in the spine[21]. This infection rate is preceded by S. aureus and S. epidermidis which 
are the primary cause of infection in the majority of postoperative spinal infections[21]. These 
species are prevalent in human epithelia residing on most skin and mucous membranes and are 
known to cause nosocomial infections in newborns, severely ill and immuno-compromised 
patients[25]. Further studies on biopsies of the spine by Heyer et al reveal the presence of all of 
these bacteria, highlighting the relevance of this study[26].  
 For this work, a novel GPC formulation alongside Simplex + Tobramycin, Spineplex and 
Novabone Putty, were tested against E. coli, S. epidermidis, P. aeruginosa and S. aureus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Materials and Methods 
 
2.1 Materials  
 Simplex P + Tobramycin (STob.) - Stryker Howmedica, Limerick, Ireland (#0473S024). 
 BT 101 + 10wt% TSC (BTSC) - Experimental GPC. 
 Spineplex (Spine) - Stryker Howmedica, Limerick, Ireland (#V1104). 
 Novabone Putty (NPut.)- Gian Medical, Birmingham, UK (#0610D5). 
 
2.1.1      Glass Synthesis 
 
A strontium-calcium-zinc-silicate glass formulation (0.04SrO/0.12CaO/0.36 ZnO/0.48 
SiO2, mol. fraction) was synthesized. The glass was prepared by weighing out appropriate 
amounts of analytical grade reagents (Sigma-Aldrich, Dublin, Ireland) and ball milling for one 
hour. The mixture was then dried in an oven (100ºC, 1 hour), fired (1480ºC, 1 hour) in a 
platinum crucible and shock quenched in water. The resulting frit was dried, ground and sieved 
to retrieve a glass powder with a maximum particle size of 45 m. 
 
2.1.2     Polyacrylic Acid (PAA) 
 
The Polyacrylic Acid (PAA) used in this study (E9, Mw 80,800) was supplied by 
Advanced Healthcare Limited (Kent, UK). The polyacrylic acid was ground and sieved to 
retrieve <90μm particles. 
2.1.3     Tri-Sodium Citrate (TSC) 
 
The TSC used in this study was obtained from Reagacon (Shannon, Ireland) and was 
incorporated into the cement at 10 wt% addition. 
 2.1.4 Tobramycin Sulfate (Tob) 
 
The Tob used in this study was obtained from Stryker Howmedica (Limerick, Ireland) 
and was incorporated into the cement at 2.5 wt% addition; a concentration similar to that 
contained in STob. 
 
2.1.5 Cement Preparation 
 
Cements were prepared by thoroughly mixing the glass powder with the PAA and 
distilled water (BT 101) on a glass plate using a dental spatula at a powder to liquid ratio of 2:1.5 
g/mL. Additions of 10 wt% TSC / 2.5wt% Tob were also added to the cement formulations as 
outlined in table 1. 
 
Table 1 Formulation of cements used in this study. 
 
 
 
 
 
 
 
 
2.2 Sample Preparation 
 
Three specimens of STob, BTTSC, Spine and NPut were used for testing in each bacterium. Each 
sample was produced by filling moulds (2 mm x 8 mmØ) with the cement and leaving them to 
set for 1 hr prior to testing. Samples were produced under standard sterile laboratory conditions. 
A short maturation study was undertaken to determine the antibacterial properties of the 
experimental GPC containing Tobramycin (BTob) against STob. For this study both materials were 
immersed in similar concentrations of sterile water for 1, 7 and 14 days. The cement were then 
 
Cement Formulations 
  Glass  PAA H2O TSC Tob 
 
BT 101 
 
BTSC 
 
1 
 
1 
 
0.37 
 
0.37 
 
0.37 
 
0.37 
 
~ 
 
0.075 
 
~ 
 
~ 
 
B Tob 
 
1 
 
0.37 
 
0.37 
 
~ 
 
0.018 
tested in S. epidermidis at 0, 1 ,7 and 14 days. A similar quantity of antibiotic was added to the 
GPC formulation, 2.5wt%, as is contained in STob.  
 
2.3 Agar Disc-Diffusion Test 
The antibacterial activity of the cements was evaluated against E. coli strain DH5α, B, S. 
epidermidis strain NCIMB 12721, P. aeruginosa strain PA01 and S. aureus strain A35-4 using 
the agar disc-diffusion method.  Luria agar and broth were used for the culture of E. coli, BHI 
agar and broth were used for culturing S. epidermidis, P. aeruginosa and S. aureus.  All 
organisms were grown at 37ºC.  Preparation of the agar disc-diffusion plates involved seeding 
the agar plates with a sterile swab dipped in a 1/50 dilution of the appropriate 16 h culture of 
bacteria. Three discs of each material were placed on the inoculated plates and the plates were 
cultured for 24 hours at 37ºC. The agar diffusion test was performed under standard laboratory 
sterile conditions using a fumigation hood with sterile swabs for inoculation of bacteria. 
Electronic calipers were used to measure zones of inhibition at three different diameters for 
each disc and zone sizes were calculated as follows: 
 
  ….. Equation 1 
 
All cements were analysed in triplicate and mean zone sizes ± standard deviations were 
calculated. 
 
2.4 Preparation of Agar Specimens 
Agar strips (3 x 10 x 5mm) were prepared for investigation by EDX from the agar 
diffusion test. The specimens were cut from the assay, extending from the cement disc, through 
any inhibition zone, through to the bacterial colony. The agar specimens were then placed on a 
glass slide and incubated at 37
o
C in an air assisted oven for 24 hours until dry.  
2.5 Quantitative EDX  
A Hitachi SU-70 field emission scanning electron microscope (FE-SEM) equipped with 
an Oxford Instruments Energy Dispersive X-ray spectroscopy (EDX) system was used to obtain 
secondary electron images and carry out chemical analysis of the agar samples. All EDX spectra 
were collected at 20 kV and quantitative EDX converted the collected spectra into concentration 
data by using standard reference spectra obtained from pure elements under similar operating 
parameters. 
 
2.6 Statistical analysis 
One-way analysis of variance (ANOVA) was employed to compare the antibacterial 
efficacy of the experimental materials in relation to 1) specific bacterial strains 2) maturation 
when implanted with an antibiotic. Comparison of relevant means was performed using the post 
hoc Bonferroni test. Differences between groups was deemed significant when p ≤ 0.05. 
Statistical analysis was performed using SPSS software for windows version 16 (SPSS Inc. 
Chicago, IL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Results and Discussion 
 
The primary objective of this study was to investigate the antibacterial response of a number 
of commercially available materials and one experimental material in an in vitro model. The first 
bacterium tested was a gram -ve aerobic bacteria, E. Coli, an opportunistic pathogen reported by 
Rafiq et al, to account for 6% of all organisms infecting Total Hip Arthroplastys (THR) from the 
period 1974-2005[5]. Research by van de Brand et al also found that E. coli was present in 60% 
of cultures where intermittent catheterization was required in joint arthroplasty[27]. In relation to 
this study the biomaterials tested had more success in eliminating E. coli than any of the other 
bacteria examined. Figure 1 shows sample images of the agar diffusion test performed with S. 
epidermidis Figure 2 a.) shows the commercial materials and experimental GPC tested against E. 
coli.  
 
 
 
Figure 1 Cements tested in S. epidermidis where a.) STob, b.) BTSC, c.) Spine and d.) NPut. 
 
 
  
 
Figure 2 Antibacterial properties of experimental materials in a.) E. coli, b) S. epidermidis, c.) P. aeruginosa & d.) 
S. aureus. 
 
 
 
Table 2 Analysis of variance (Bonferroni post-hoc) between biomaterials and bacteria Spp. 
 
E.coli P.aeruginosa S.epidermidis S.aureus
STob  vs. BTSC 0.001 0.000 0.000 0.000
STob  vs. Spine 0.000 0.000 0.000 0.000
STob  vs. NPut 0.000 0.000 0.000 0.000
BTSC  vs. Spine 0.000 1.000 1.000 1.000
BTSC  vs. NPut 0.000 1.000 1.000 1.000
Spine  vs. NPut 1.000 1.000 1.000 1.000  
 
                       * The mean difference is significant at the 0.05 level. 
 
 
From figure 2 a.) it can be seen that STob proved to be the most effective in killing E.coli; 
achieving inhibition zones of 8.3±1.69mm. However, the experimental GPC, BTSC produced 
inhibition zones of 5.9±0.05mm. Both Spine and NPut did not produce any zones of inhibition in E. 
coli. Statistical analysis was performed between each material for variance, and this was done for 
each bacterium. It was found that there are significant differences between the two cements that 
showed inhibition, STob and BTSC (p=0.001). STob and BTSC showed significant differences when 
compared with all other materials tested, (figure 2 a.) also there was found to be no significant 
difference between Spine and NPut (p=1.000), as these materials showed no inhibition. This was 
similar for all bacterium tested where Spine and NPut showed no inhibition for S. epidermidis, P. 
aeruginosa and S. aureus (p=1.000) as shown in figure 2 b.), c.) & d.). STob showed significant 
differences in each bacterium where it produced inhibition zones of 13.3±0.4mm for S. 
epidermidis, 14.9±1.3mm for P. aeruginosa and 7.8±0.5mm for S. aureus. These results were 
also significantly different to all other materials (table 2) as no other material produced clear 
inhibition zones for S. epidermidis, P. aeruginosa and S. aureus. However, some antibacterial 
efficiency was observed with BTSC when tested in S. epidermidis (figure 1). Inhibition zones were 
not recorded as isolated colonies of bacteria were present within the inhibition zone. This 
indicates that BTSC is bacteriostatic in relation to S. epidermidis and not bacteriocidal. BTSC is 
likely to be inhibiting the growth and proliferation of this bacteria as opposed to killing the cells 
outright. 
With respect to each bacteria, STob was found to be bacteriocidal and outperformed each 
of the competing materials. This is due to the presence of the antibiotic Tobramycin (Tob). Tob is 
is generally used to treat gram-ve bacterial infections such as skin or bone, lower respiratory tract 
and central nervous system (CNS) infections [28]. Studies by Le Goffic et al describes Tob 
mechanism of action in relation to E. coli. Tob was found to occupy two binding sites on the 
ribosomes of the bacterial cell. The primary one is likely responsible for the inhibition of protein 
synthesis whereas the secondary one is related to the misreading of the messenger RNA[29]. Tob 
has also previously been used to treat P. aeruginosa infections in patients with cystic fibrosis[30, 
31], and has been described by D’Arrigo et al to show excellent in vitro and clinical activities 
against susceptible strains of E. coli and S. aureus by inhibiting plasma membrane functions and 
by targeting ribosomal sites[32]. However, overuse of antibiotics in medicine promoted the 
evolution of some species of bacteria to infer resistance. These include the Methicillin resistant 
S.aureus (MRSA) and S. epidermidis (MRSE) strains which are responsible for a considerable 
amount of hospital acquired infections [33-35]. The primary reason for increased usage of 
antibiotics in implant related infections is that bacteria change their biological behavior when 
adhering to implant surfaces[2]. They produce a biofilm which forms a protective barrier and 
they can also reduce their metabolic activity and increase their generation time. As antibiotics act 
on growing bacteria, an increased minimum inhibitory concentration (MIC) of antibiotic is 
required to affect bacteria with reduced metabolic activity. Studies have found that 800 fold 
higher MIC for Tob in adhesive P. aeruginosa than for non-adhesive [2, 7]. Concerns also arise 
regarding the quantity of antibiotic released and the longevity around the implant site. After the 
high initial release of antibiotics, the long-term low concentration around implants may also 
contribute to antibiotic resistant strains[2, 7]. The effectiveness of such materials is dependent on 
the rate and manner of which the drug is released, and this is directly related to the host 
material[7]. Drug release from materials is achieved through mechanisms of water pore 
penetration, soluble matrix dissolution and diffusion of the solubilized drug via matrix 
imperfections (pores/cracks). However PMMA based materials display a biphasic release pattern 
characterized by a high initial release followed by a long tail of low, ineffective and largely 
incomplete release that continues for days or months. Studies reveal that less than 10% of the 
trapped drug is eventually released from the cement[7]. Another concern is that antibiotics such 
as Tob can have harmful side effects in the body. Tob belongs to a group called aminoglycosides 
which are known to be nephrotoxic and ototoxic, depending on the choice of aminoglycoside and 
duration of therapy[36]. Increasing the dosage of antibiotic to reach the MIC when combating 
adherent biofilms may subsequently result in more trauma to local tissues. 
To determine the efficacy of antibiotic release from STob and a GPC (BTob), testing was 
performed on S. epidermidis over a period of 0-14 days. Figure 3 shows the comparison of STob 
and BTob in S. epidermidis with respect to maturation.  
 
 
 
Figure 3 Comparison of STob and BTob in S. epidermidis with respect to maturation. 
 
 
Table 3 Analysis of variance (Bonferroni post-hoc) between STob and BTob in S. epidermidis with respect to 
maturation. 
 
 
a.) Time (Days) STob BTob
0 vs. 1 0.000 1.000
0 vs. 7 0.000 0.043
0 vs. 14 0.000 0.041
1 vs. 7 0.589 0.021
1 vs. 14 1.000 0.020
7 vs. 14 1.000 1.000
b.) 0 day 0.000
14 day 0.001
STob. vs. BTob
 
 
* The mean difference is significant at the 0.05 level. 
From figure 3 it can be seen that there is a significant decrease in antibacterial efficacy 
from 0 days (17.4±0.4mm) through to 14 days (9.8±0.01mm) regarding STob. However there is 
no significant change when comparing 1, 7 and 14 days (p=0.589, 1.000, 1.000 table 3a). This 
suggests that the set material is retaining some of the antibiotic in the bulk and that the surface 
antibiotic has solubilized and was expended after initial testing at 0 days. BTob on the other hand 
was found to show a significant (p=0.041) increase in inhibition over the period of 0 days 
(5.7±0.4mm) to 14 days (7.4±0.3mm). It was expected that BTob would perform better than the 
results obtained here as GPCs are ion leachable materials. However this may be the reason for 
the lower results found as compared to STob. It may be possible that ion processes within the 
cement are reducing the efficacy of the antibiotic. Considering this, however, antibacterial 
efficacy was found to increase with respect to maturation. Table 3b confirms that there remains a 
significant change in inhibition between STob and BTob at initial testing, 0 days and after 14 days. 
Further testing to 30 or 90 days may provide more conclusive results regarding the longevity and 
efficacy of antibiotic implanted materials. 
Further testing was performed to determine what was causing the antibacterial efficacy of 
the materials. This was achieved by performing EDX on agar specimens from the agar extracted 
from the area immediately surrounding the samples, whether inhibition was present or not. 
Figure 4 shows the EDX results obtained from a.) STob, b.) BTSC, c.) Spine and d.) NPut.  
 
 
 
Figure 4 EDX of agar samples comparing control agar with agar from plates containing materials. 
 
 
It is evident from figure 4a that there is little change in the composition of the agar 
regarding STob. This is due to EDX not being able to identify complex chemical structures. 
Figure 4b reveals the presence of approximately 1wt% Zn whereas no Zn was found in the 
control agar. There was also a small quantity of Sr (0.1wt%) detected, where again, no Sr was 
present in the control agar. It is difficult to determine the precise mechanism by which BTSC is 
exhibiting antimicrobial properties as TSC present in the cement is known to be an antibacterial 
agent itself [37, 38]. Previous work by the authors determined that TSC prolongs the setting [39] 
of this cement facilitating greater ion release[40]. It has also been previously been reported that 
by increasing the concentration of TSC and Zn ion release, the antibacterial efficacy of the 
material increases[40]. Zn is an antibacterial ion which acts as an inhibitor of multiple activities 
in the bacterial cell, such as glycolysis, transmembrane proton translocation and acid 
tolerance[41]. It has also been cited by Shashibhushan et al that Zn can interfere with substrate 
transport and oxidation and can react with thiol groups on the bacterial cell wall[18]. Zn can also 
change protein structure leading to inhibition of specific metabolic enzymes, thereby causing 
growth inhibition[18]. Another possible reason for inhibition by BTSC could be explained by the 
mechanism of action of TSC, which is known to chelate Ca[42], which in this case slows the 
setting reaction in these cements[39]. However, regarding bacterial inhibition, TSC may be 
binding any Ca being used by the bacteria for metabolism. There was no antibacterial effect 
attributed to Spine and NPut, however there were slight changes in the EDX patterns. Figure 4c 
shows that there was an increase in the phosphorus (P) concentrations as compared to the control 
agar. This may be due to bacteria metabolising as they proliferate on the surface of the agar. 
There was also a very slight increase in P content in the agar surrounding NPut (figure 4d). These 
materials exhibited no antibacterial properties when tested against these bacteria as Spine, in 
particular, contains no antimicrobial compounds or ions. This cement is implanted and remains 
as an inert material exhibiting no bioactivity. NPut is based on a Bioglass formulation suspended 
in a gelatin binder, however the composition failed to inhibit the proliferation of the bacteria 
tested. 
To conclude, STob was the only material to exhibit antibacterial properties when tested in 
each bacterium. However the ongoing discussion as regards the overuse of antibiotics suggests 
that additional ways of combating infection would be welcome. BTSC was the only other material 
to exhibit antibacterial properties and this was only evident against E. coli and S. epidermidis. 
The advantage of using a GPC over an acrylic cement is that beneficial ions can be absorbed and 
re-released when in an ion rich environment. However further research is required to evaluate at 
what extent this occurs. Spine and NPut are two commercially available materials that were found 
to exhibit no antibacterial properties, and as such this leaves room for development of more 
bioactive materials with properties suitable for use in orthopaedics. 
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